Cytochrome P450 17 (CYP17) Inhibitors - Pipeline Insights, 2017

Description: "Cytochrome P450 17 (CYP17) Inhibitors - Pipeline Insights, 2017" provides in depth insights on the pipeline drugs and their development activities around the Cytochrome P450 17 (CYP17) Inhibitors. This report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Cytochrome P450 17 (CYP17) Inhibitors. This report also assesses the Cytochrome P450 17 (CYP17) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please Note: This report requires certain updates. We have all the information available but require 2 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope:
- The report provides competitive pipeline landscape of Cytochrome P450 17 (CYP17) Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Cytochrome P450 17 (CYP17) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Cytochrome P450 17 (CYP17) Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Delivery Time: 2 Working Days.

Contents:
- Cytochrome P450 17 (CYP17) Inhibitors Overview
- Cytochrome P450 17 (CYP17) Inhibitors Disease Associated
- Cytochrome P450 17 (CYP17) Inhibitors Pipeline Therapeutics
- Cytochrome P450 17 (CYP17) Inhibitors Therapeutics under Development by Companies
- Cytochrome P450 17 (CYP17) Inhibitors Filed and Phase III Products
- Comparative Analysis
- Cytochrome P450 17 (CYP17) Inhibitors Phase II Products
- Comparative Analysis
- Cytochrome P450 17 (CYP17) Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- Cytochrome P450 17 (CYP17) Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Cytochrome P450 17 (CYP17) Inhibitors - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cytochrome P450 17 (CYP17) Inhibitors - Discontinued Products
- Cytochrome P450 17 (CYP17) Inhibitors - Dormant Products
- Companies Involved in Therapeutics Development for Cytochrome P450 17 (CYP17) Inhibitors
- Appendix
- Methodology
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cytochrome P450 17 (CYP17) Inhibitors by Therapy Area, 2017
Number of Products under Development for Cytochrome P450 17 (CYP17) Inhibitors, 2017
Number of Products under Development by Companies
Comparative Analysis by Filed and Phase III Products, 2017
Comparative Analysis Phase II Products, 2017
Comparative Analysis Phase I and IND Filed Products, 2017
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
Drug Candidates Profiles
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Monotherapy Products
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Combination Products
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Route of Administration
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Stage and Route of Administration
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Molecule Type
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Stage and Molecule Type
Cytochrome P450 17 (CYP17) Inhibitors Therapeutics - Discontinued Products
Cytochrome P450 17 (CYP17) Inhibitors Therapeutics - Dormant Products
Products under Development by Companies, 2017

List of Figures
Number of Products under Development for Cytochrome P450 17 (CYP17) Inhibitors by Therapy Area, 2017
Number of Products under Development for Cytochrome P450 17 (CYP17) Inhibitors, 2017
Filed and Phase III Products, 2017
Phase II Products, 2017
Phase I and IND Filed Products, 2017
Discovery and Pre-Clinical Stage Products, 2017
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Monotherapy Products
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Combination Products
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Route of Administration
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Stage and Route of Administration
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Molecule Type
Cytochrome P450 17 (CYP17) Inhibitors Assessment by Stage and Molecule Type

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/4037592/](http://www.researchandmarkets.com/reports/4037592/)

Order by Fax - using the form below

Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Cytochrome P450 17 (CYP17) Inhibitors - Pipeline Insights, 2017
Web Address: http://www.researchandmarkets.com/reports/4037592/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 1250</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 3750</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp